Valsamo Anagnostou
The Johns Hopkins Hospital
Office
(410) 955-5000
Fax (410) 955-5001 1800 Orleans Street Baltimore, MD 21287
About
Dr. Anagnostou graduated from Medical School of the National and Kapodistrian University of Athens, Greece and received a PhD from the same institution. After completing her internal medicine residency at Yale-New Haven Hospital, she subsequently trained in Medical Oncology at Johns Hopkins.
Dr. Anagnostou is a translational cancer investigator, focusing on large-scale genomic and liquid biopsy analyses in human cancers. Her group has discovered novel genomic mechanisms of response and resistance to immunotherapy and her research is particularly focused on understanding the molecular mechanisms of response and resistance to these therapies, capturing these by minimally invasive methods and translating this knowledge into novel technologies and innovative therapeutic approaches for cancer patients. She is the international study chair of the first ctDNA-based molecular response adaptive immuno-chemotherapy clinical trial for metastatic non-small cell lung cancer (NCT04093167).
Dr. Anagnostou's long term goal is to transform medical oncology to personalized molecular oncology, where treatment decisions are tailored to cancer genomics and molecular real-time response assessments informed by liquid biopsies.
Valsamo Anagnostou
Dr. Anagnostou is an Associate Professor of Oncology, co-director of the Upper Aerodigestive Malignancies Program, director of the Thoracic Oncology Biorepository, leader of Precision Oncology Analytics and co-leader of the Molecular Tumor Board and the Thoracic Oncology Precision Medicine Center of Excellence in the Sidney Kimmel Cancer Center at Johns Hopkins. She has established the Molecular Oncology laboratory that seeks to understand the genomic wiring of response and resistance to immunotherapy through integrative genomic, transcriptomic, single-cell and liquid biopsy analyses of tumor and immune evolution.Dr. Anagnostou graduated from Medical School of the National and Kapodistrian University of Athens, Greece and received a PhD from the same institution. After completing her internal medicine residency at Yale-New Haven Hospital, she subsequently trained in Medical Oncology at Johns Hopkins.
Dr. Anagnostou is a translational cancer investigator, focusing on large-scale genomic and liquid biopsy analyses in human cancers. Her group has discovered novel genomic mechanisms of response and resistance to immunotherapy and her research is particularly focused on understanding the molecular mechanisms of response and resistance to these therapies, capturing these by minimally invasive methods and translating this knowledge into novel technologies and innovative therapeutic approaches for cancer patients. She is the international study chair of the first ctDNA-based molecular response adaptive immuno-chemotherapy clinical trial for metastatic non-small cell lung cancer (NCT04093167).
Dr. Anagnostou's long term goal is to transform medical oncology to personalized molecular oncology, where treatment decisions are tailored to cancer genomics and molecular real-time response assessments informed by liquid biopsies.
Primary Specialty
Oncologist
Practice
The Johns Hopkins Hospital
Gender
Female
Not Accepting New Patients
Degrees
Medical Doctor
Office Name
The Johns Hopkins Hospital
Languages
Greek, English
Services
The Johns Hopkins Hospital provides oncology services in Baltimore, MD. Oncology includes the diagnosis and treatment of breast cancer, skin cancer, prostate cancer, and many other forms of cancer.
Contact Valsamo Anagnostou at (410) 955-5000 for specific information about cancer treatment in Baltimore, MD.
Contact Valsamo Anagnostou at (410) 955-5000 for specific information about cancer treatment in Baltimore, MD.
Consumer Feedback
Add a Review
There are no recent reviews. Be the first!